Felicetto Ferrara

Educazione:

• Data di nascita: 28/5/1954
• Laurea: Medicina e Chirurgia (1978, Univeristà di Napoli)
• Specializzazione in Ematologia, (1981, Università di Genova)
• Specializzazione in Oncologia (1987, Università di Napoli)

Professione

• 1980-1990: Assistente presso la divisione di Ematologia dell’Ospedale Cardarelli di Napoli
• 1990-2000: Aiuto presso la divisione di Ematologia dell’Ospedale Cardarelli di Napoli
• dal 2000: Primario presso la divisione di Ematologia dell’Ospedale Cardarelli di Napoli

Aree di interesse

• Diagnosi prognosi e terapia delle emopatie neoplastiche con particolare riguardo alle leucemie acute
• Autotrapianto di cellule staminaliemopoietiche.

Premi e incarichi

• Membro dell’editorialboard di Haematologica fino al 2007
• Membro del Working Party GIMEMA per le leucemie acute Menbro della Società Italiana di Ematologia
• Membro dell’EHA (EuropeanHematologyAssociation)
• Membro dell’American Society of Hematology Reviewer per le riviste: Blood, The Lancet, Lancet Oncology, British Journal of Haematology, Haematologica, Bone Marrow Transplantation, Drugs, European Journal of Hematology

Pubblicazioni selezionate

1. Ferrara F. Treatment of older patients with acute myeloid leukaemia. Lancet. 2010;376:1967-8.
2. Ferrara F, Palmieri S, Izzo T, Criscuolo C, Riccardi C. Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome. Hematol Oncol. 2010;28:202-8
3. Ferrara F, Izzo T, Criscuolo C, Riccardi C, Viola A, Delia R, Carbone A, Celentano M. Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis. Hematol Oncol. 2010 Nov 30. [Epubahead of print]
4. Ferrara F, Izzo T, Criscuolo C, Riccardi C, Celentano M, Mele G. Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results. Am J Hematol. 2010;85:687-90
5. Ferrara F, Izzo T, Criscuolo C, Riccardi C, Muccioli G, Viola A, Pane F, Palmieri S. Favorable outcome in patients with acute myeloid leukemia with NPM1 mutation autografted after conditioning with high dose continuous infusion idarubicin and busulphan. Biol Blood Marrow Transplant. 2010;16:1018-24.
6. Ferrara F, Finizio O, D’Arco A, Mastrullo L, Cantore N, Musto P. Acute promyelocytic leukemia in patients aged over 60 years: multicenter experience of 34 consecutive unselected patients. Anticancer Res. 2010;30:967-71.
7. Ferrara F, Palmieri S, Mele G. Peripheral blood or bone marrow as hematopoietic stem cell source for autologous transplantation in acute myeloid leukemia? J ClinOncol. 2010;28:e246-7
8. Ferrara F. Acute promyelocytic leukemia: what are the treatment options? Expert Opin Pharmacother. 2010;11:587-96
9. Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, Ferrara F, Altucci L, Stunnenberg HG. PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell. 2010;17:173-85.
10. Ferrara F, Criscuolo C, Riccardi C, Izzo T, Pedata M, Copia C, Vicari L, Tarsitano M, Palmieri S, Pane F. FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype. Am J Hematol. 2009;84:532-5